Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference

Abstract:
BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics which address resistance issues in cancer, HIV and opportunistic infections, today announced that it will take part in an international business conference devoted to meetings between institutional investors and healthcare/biotech companies:

* The Natixis Securities MidCap Healthcare Conference, November 16, Paris.

(at Salons France Amériques, 9-11 Avenue Franklin Roosevelt)

Dominique Costantini, BioAlliance Pharma's President and CEO, will present the company to institutional investors in plenary session #1 at 9.45am on Friday, November 16.

Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference

PARIS, France | Posted on November 12th, 2007

BioAlliance is the first French high-growth company to have developed a product on the basis of innovative academic research results and to have completed the drug development process all the way up to and including market launch. With a broad and diversified portfolio of innovative products (including three in Phase III trials and a number of promising preclinical programs in cancer and HIV), the company has highlighted its determination to achieve growth throughout Europe.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance. The company is currently developing three innovative clinical-phase products based on the Lauriad® muco-adhesive technology (which enables early, prolonged release of therapeutic agents at the site of the disease; one product is already on the market in France and two phase III clinical trials are ongoing - Loramyc® and acyclovir Lauriad®) and the Transdrug® nanoparticle technology (designed specifically for intracellular targeting of resistant cells: a pivotal phase III primary liver cancer trial is underway with doxorubicin Transdrug®). The company is also developing a new therapeutic entities program focused on the oncology and HIV market.

In 2007, the company established two strategic partnerships to sell its first product (Loramyc®) in the USA and Europe (where the French market launch was announced in September 2007).

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma S.A.'s website ( http://www.bioalliancepharma.com ).

For press releases and other company information, visit http://www.bioalliancepharma.com .

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
President and CEO
Tel.: +33 1 45 58 76 01

or
Nicolas Fellmann
CFO
Tel.: +33 1 45 58 71 00

or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016

Tunneling nanotubes between neurons enable the spread of Parkinson's disease via lysosomes August 24th, 2016

Announcements

A nanoscale wireless communication system via plasmonic antennas: Greater control affords 'in-plane' transmission of waves at or near visible light August 27th, 2016

Forces of nature: Interview with microscopy innovators Gerd Binnig and Christoph Gerber August 26th, 2016

A promising route to the scalable production of highly crystalline graphene films August 26th, 2016

Graphene under pressure August 26th, 2016

Events/Classes

Stretchy supercapacitors power wearable electronics August 25th, 2016

Semblant to Present at China Mobile Manufacturing Forum 2016 August 25th, 2016

Nanoparticles that speed blood clotting may someday save lives August 23rd, 2016

Impressive List of Doctors, Scientists Coming to Vail for Scientific Summit: The Second Vail Scientific Summit Convenes the Greatest Minds in Regenerative Medicine and Science August 17th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic